Buscar
Trinity Biotech PLC
TRIBAñadir a la lista de seguimiento
11.670USD
-0.130-1.10%
Cierre 08-14 16:00（ET）Cotizaciones retrasadas 15 min
7.52MCap. mercado
PérdidaP/E TTM
Más Datos de Trinity Biotech PLC Compañía
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Perfil de Trinity Biotech PLC
Símbolo de cotizaciónTRIB
Nombre de la empresaTrinity Biotech PLC
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 21
DirecciónIda Business Park, Bray, Co Wicklow
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal18
Teléfono01135312955111
Sitio Webhttps://www.trinitybiotech.com/
Símbolo de cotizaciónTRIB
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)
Ejecutivos de Trinity Biotech PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Paul Tivnan
Mr. Paul Tivnan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Murphy
Mr. Paul Murphy
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. David Gentry
Mr. David Gentry
IR Contact Officer
IR Contact Officer
--
--
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Trinity Biotech PLC?
Los cinco principales accionistas de Trinity Biotech PLC son: Mr. Ronan O'Caoimh
¿Cuántas instituciones poseen acciones de Trinity Biotech PLC (TRIB)?
A fecha de 2026Q1, 50 instituciones poseen acciones de Trinity Biotech PLC, con un valor de mercado combinado de aproximadamente 876.37K, lo que representa el 4.33% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2074917.00.
¿Cuál es la mayor fuente de ganancias de Trinity Biotech PLC?
El 2026Q1, el segmento empresarial Clinical Laboratory generó la ganancia más alta para Trinity Biotech PLC, ascendiendo a 42.29M y representando el 74.41% de la ganancia total.